Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins
About this study
The study aims to reduce the PTV (Planning Target Volume) safety margins to 1-2 mm in stereotactic prostate radiotherapy for low- and medium-risk prostate cancers while maintaining a dose of 36.25 Gy in 5 fractions per day. By reducing the hems, the investigators expect a reduction of acute and late toxicity on the organs at risk, dominantly the urethra, bladder, penile bulb, and rectum, and an improvement in the quality of life.
- Condition
- Prostate Cancer (Adenocarcinoma)
- Tested
- Stereotactic radiotherapy
- Sponsor
- University Hospital Ostrava
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 12
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Prostate Cancer (Adenocarcinoma)
- histologically verified, localized prostate cancer without regional lymphadenopathy or distant metastases
- low or intermediate risk - favorable risk
- staging according to NCCN recommendations:
- low risk: no staging required
- intermediate risk- favorable risk: CT abdomen and pelvis
- PSA up to 15
- age over 18 years
- signed informed consent form
- suitable position of fiducials (to be determined by the physicist)
Exclusion 6
- a histological type other than acinar adenocarcinoma
- the presence of local lymphadenopathy or distant metastases
- a dominant lesion in the periphery that is in contact with the capsule or grows through it
- PSA over 15
- unsatisfactory position of fiducials (to be determined by the physicist)
- previous treatment with radiotherapy to the pelvic area
Where
1 site, 1 recruiting
University Hospital Ostrava
Ostrava, Moravian-Silesian Region, Czechia
Contact
-
Jiří Hynčica
0042059737 jiri.hyncica@fno.cz
Potential match only. Final eligibility is determined by the study team.